Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 4/20 | 0.62 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.56 |
| ▸ | UBE2M | P61081 | 3/20 | 0.56 |
| ▸ | DCUN1D1 | Q96GG9 | 3/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3124201 | 0.91 | OPRL1 (0.60) | OPRL1CHRM4UBE2MDCUN1D1DRD4 | |
| SCHEMBL3126478 | 0.88 | OPRL1 (0.56) | OPRL1CHRM4UBE2MDCUN1D1DRD4 | |
| Hydrochloric Acid SCHEMBL4814838 | 0.87 | OPRL1 (0.55) | OPRL1CHRM4UBE2MDCUN1D1DRD4 | |
| SCHEMBL702418 | 0.86 | KDM4E (0.66) | OPRL1OPRM1KDM4EOPRD1 | |
| SCHEMBL3136902 | 0.84 | OPRL1 (0.86) | OPRL1CHRM4DRD4OPRM1LMNA | |
| SCHEMBL2794291 | 0.83 | OPRL1 (0.64) | OPRL1USP2SIGMAR1OPRM1KDM4E | |
| Hydrochloric Acid SCHEMBL4813917 | 0.83 | OPRL1 (0.84) | OPRL1CHRM4DRD4OPRM1KDM4E | |
| SCHEMBL699951 | 0.82 | OPRL1 (0.63) | OPRL1CHRM4DRD4USP2SIGMAR1 | |
| Hydrochloric Acid SCHEMBL2793069 | 0.82 | POLB (0.65) | OPRL1USP2SIGMAR1OPRM1KDM4E | |
| SCHEMBL696251 | 0.82 | AKR1C3 (0.67) | OPRL1OPRM1HTTKMT2AAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1699778-B1 | (4-PHENYLPIPERAZIN-1-YL)ACYLPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2010-07-14 | — | — | EP | disclosed |
| US-7468368-B2 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI AVENTIS (FR) | 2008-12-23 | — | — | US | disclosed |
| US-7423039-B2 | (4-phenylpiperazin-1-yl)acylpiperidine derivatives, preparation thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2008-09-09 | — | — | US | disclosed |
| US-7294628-B2 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-11-13 | — | — | US | disclosed |
| US-20070021609-A1 | 4-PHENYLPIPERAZIN-1-YL)ACYLPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | disclosed |
| EP-1699778-A1 | (4-PHENYLPIPERAZIN-1-YL)ACYLPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2006-09-13 | — | — | EP | disclosed |
| EP-1513835-B1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2006-08-16 | — | — | EP | disclosed |
| US-20060167007-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2006-07-27 | — | — | US | disclosed |
| EP-1513836-B1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2006-05-03 | — | — | EP | disclosed |
| US-20050176722-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2005-08-11 | — | — | US | disclosed |
| WO-2005054227-A1 | (4-PHENYLPIPERAZIN-1-YL)ACYLPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2005-06-16 | — | — | WO | disclosed |
| EP-1513836-A1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2005-03-16 | — | — | EP | disclosed |
| EP-1513835-A1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003104225-A1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003104226-A1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021609-A1 | 4-PHENYLPIPERAZIN-1-YL)ACYLPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | AGPAT5, DNPEP, AGPAT2 | OPRL1 2532/4885CHRM4 2925/4885UBE2M 4647/4885 |
| US-20060167007-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | NR5A2, NR3C2, NR3C1 | OPRL1 29/4885CHRM4 183/4885UBE2M 4041/4885 |
| US-20050176722-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | NR5A2, NR3C1, CBR1 | OPRL1 24/4885CHRM4 135/4885UBE2M 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.